JP5562510B2
(ja)
|
2001-06-28 |
2014-07-30 |
ノヴォ ノルディスク アー/エス |
修飾glp−1の安定な処方剤
|
ATE541582T1
(de)
|
2003-06-03 |
2012-02-15 |
Novo Nordisk As |
Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen
|
EP1633391B1
(en)
|
2003-06-03 |
2011-10-19 |
Novo Nordisk A/S |
Stabilized pharmaceutical peptide compositions
|
KR101243648B1
(ko)
|
2003-11-20 |
2013-03-14 |
노보 노르디스크 에이/에스 |
제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제
|
EP1789434B1
(en)
|
2004-08-31 |
2013-11-20 |
Novo Nordisk A/S |
Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
|
CA2586771A1
(en)
|
2004-11-12 |
2006-05-18 |
Novo Nordisk A/S |
Stable formulations of insulinotropic peptides
|
WO2007056362A2
(en)
|
2005-11-07 |
2007-05-18 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting physiological solubility and stability
|
EP2124974B1
(en)
*
|
2007-01-05 |
2017-03-15 |
Indiana University Research and Technology Corporation |
Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
|
EP2111414B1
(en)
|
2007-02-15 |
2014-07-02 |
Indiana University Research and Technology Corporation |
Glucagon/glp-1 receptor co-agonists
|
WO2009058734A1
(en)
|
2007-10-30 |
2009-05-07 |
Indiana University Research And Technology Corporation |
Compounds exhibiting glucagon antagonist and glp-1 agonist activity
|
ES2509883T3
(es)
|
2007-10-30 |
2014-10-20 |
Indiana University Research And Technology Corporation |
Antagonistas de glucagón
|
KR20110039230A
(ko)
|
2008-06-17 |
2011-04-15 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
생리학적 pH 완충액에서 강화된 용해도 및 안정성을 나타내는 글루카곤 유사체
|
EA019203B9
(ru)
|
2008-06-17 |
2014-03-31 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Коагонисты глюкагонового рецептора/glp-1-рецептора
|
US9062124B2
(en)
|
2008-06-17 |
2015-06-23 |
Indiana University Research And Technology Corporation |
GIP-based mixed agonists for treatment of metabolic disorders and obesity
|
MX344293B
(es)
|
2008-10-17 |
2016-12-13 |
Sanofi Aventis Deutschland |
Combinacion de una insulina y un agonista de glp-1.
|
TWI489992B
(zh)
|
2008-12-19 |
2015-07-01 |
印地安那大學研究及技術公司 |
醯胺系胰高血糖素超級家族之胜肽前驅藥物
|
MX2011013625A
(es)
|
2009-06-16 |
2012-01-20 |
Univ Indiana Res & Tech Corp |
Compuestos glucagon activo de receptor de gip.
|
PT2498802E
(pt)
|
2009-11-13 |
2015-04-13 |
Sanofi Aventis Deutschland |
Composição farmacêutica que compreende um agonista de glp-1, uma insulina e metionina
|
BR112012011403B8
(pt)
|
2009-11-13 |
2021-05-25 |
Sanofi Aventis Deutschland |
composição farmacêutica líquida compreendendo um agonista glp-1 e metionina e uso da mesma
|
EP2512503A4
(en)
|
2009-12-18 |
2013-08-21 |
Univ Indiana Res & Tech Corp |
COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
|
MX2012008603A
(es)
|
2010-01-27 |
2013-01-25 |
Univ Indiana Res & Tech Corp |
Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad.
|
ES2661228T3
(es)
|
2010-05-13 |
2018-03-28 |
Indiana University Research And Technology Corporation |
Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona
|
EP2568993A4
(en)
|
2010-05-13 |
2014-02-19 |
Univ Indiana Res & Tech Corp |
GLUCAGON SUPERFAMILY PEPTIDES EXPRESSING G PROTEIN-COUPLED RECEPTOR ACTIVITY
|
WO2011163012A2
(en)
|
2010-06-24 |
2011-12-29 |
Indiana University Research And Technology Corporation |
Amide based glucagon superfamily peptide prodrugs
|
RU2546520C2
(ru)
|
2010-08-30 |
2015-04-10 |
Санофи-Авентис Дойчланд Гмбх |
Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа
|
PE20140186A1
(es)
|
2010-12-22 |
2014-02-13 |
Univ Indiana Res & Tech Corp |
Analogos de glucagon que presentan actividad de receptor de gip
|
TW201236692A
(en)
*
|
2011-02-02 |
2012-09-16 |
Sanofi Aventis Deutschland |
Prevention of hypoglycaemia in diabetes mellitus type 2 patients
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
GEP20176629B
(en)
|
2011-06-22 |
2017-02-27 |
Indiana Unversity Research And Tech Corporation |
Glucagon/glp-1 receptor co-agonists
|
MX2013015168A
(es)
|
2011-06-22 |
2014-03-31 |
Univ Indiana Res & Tech Corp |
Co-agonista del receptor de glucagon/glp-1.
|
US9944687B2
(en)
|
2011-07-04 |
2018-04-17 |
Imperial Innovations Limited |
Compounds and their effects on feeding behaviour
|
US9408893B2
(en)
|
2011-08-29 |
2016-08-09 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
|
TWI559929B
(en)
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
KR20140097151A
(ko)
|
2011-11-17 |
2014-08-06 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
글루코코르티코이드 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
|
JP6311708B2
(ja)
|
2012-06-21 |
2018-04-18 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation |
Gip受容体活性を示すグルカゴンアナローグ
|
CA2878991C
(en)
*
|
2012-07-23 |
2021-12-07 |
Zealand Pharma A/S |
Glucagon analogues
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
JP2016503771A
(ja)
|
2012-12-21 |
2016-02-08 |
サノフイ |
エキセンジン−4誘導体
|
CN114376970A
(zh)
|
2013-06-28 |
2022-04-22 |
美国安进公司 |
Etelcalcetide (AMG 416)的稳定的液体制剂
|
TW201609796A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
非醯化之艾塞那肽-4(exendin-4)胜肽類似物
|
EP3080150B1
(en)
|
2013-12-13 |
2018-08-01 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
|
EP3080149A1
(en)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Dual glp-1/glucagon receptor agonists
|
WO2015086729A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Dual glp-1/gip receptor agonists
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自exendin-4之雙重glp-1/升糖素受體促效劑
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
LT3229828T
(lt)
|
2014-12-12 |
2023-06-12 |
Sanofi-Aventis Deutschland Gmbh |
Insulino glargino/liksisenatido fiksuoto santykio kompozicija
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患治療
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患之治療
|
AR105319A1
(es)
|
2015-06-05 |
2017-09-27 |
Sanofi Sa |
Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
|
AR105284A1
(es)
|
2015-07-10 |
2017-09-20 |
Sanofi Sa |
Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
|
CN111050750A
(zh)
|
2017-08-24 |
2020-04-21 |
诺沃挪第克公司 |
Glp-1组合物及其用途
|
EP3897570A1
(en)
|
2018-12-19 |
2021-10-27 |
KRKA, d.d., Novo mesto |
Pharmaceutical composition comprising glp-1 analogue
|
WO2021123228A1
(en)
|
2019-12-18 |
2021-06-24 |
Krka, D.D., Novo Mesto |
Pharmaceutical composition comprising glp-1 analogue
|
MX2022009523A
(es)
|
2020-02-18 |
2022-09-09 |
Novo Nordisk As |
Formulaciones farmaceuticas.
|
WO2022157747A2
(en)
*
|
2021-01-25 |
2022-07-28 |
Mylan Ireland Limited |
Pharmaceutical peptide compositions and methods of preparation thereof
|